To address this issue, Edwards Lifesciences convened a roundtable, including representatives from the medical device, diagnostic, and pharmaceutical industries, private hospital operators, clinicians and clinical societies, patient advocates, and other subject matter experts.
Learn how rapid Next Generation Sequencing (NGS) is unlocking a new era of precision cancer care in Australia, with faster diagnosis, more personalised treatment, and system-wide benefits.
The healthcare sector faces a critical challenge balancing the imperative to provide high-quality patient care with the urgent need to address its significan environmental impact.
One in 17 people will encounter a rare disease of genetic origin in their lifetime. Approximately half of those will be children, with 30% of those children not surviving beyond the age of 5 years.
Cardiovascular disease (CVD) is a significant public health concern in Australia, with potentially devastating effects on individuals and a substantial burden on the healthcare system.
